drugset / Trial / NCT04991116
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NaSingle-groupOpen-labelTreatment
Summary
An open label phase 3 study
Timeline
- Start
- 2022-06-30
- Primary completion
- 2028-12
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tildrakizumab | Monoclonal antibody | 1 ml | Subcutaneous |